Cell-Free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites Following Pediatric Liver Transplantation.

Authors

Itsuki Naya, Naoya Yamada, Yoshihiro Hirata, Yoshiyuki Ihara, Megumi Tamura, Motoki Ebihara, Shoichi Tsuzaka, Rina Matsuda, Shotaro Taki, Shoko Ogawa, Kyoichi Deie, Hiroshi Kawashima, Koichi Mizuta

Published in

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. Aug 28, 2026. Epub Aug 28, 2026.

Abstract

Cell-free and concentrated ascites reinfusion therapy (CART) has been widely used for malignant ascites and decompensated cirrhosis, but its perioperative application remains unclear. We evaluated CART after pediatric living donor liver transplantation (LDLT).
We retrospectively reviewed pediatric LDLT recipients who underwent CART for refractory ascites. Changes in ascites volume, protein recovery rates including albumin and immunoglobulin G (IgG), and adverse events were analyzed.
Ten recipients underwent 92 CART sessions. Median ascites volume decreased from 1785 mL to 362 mL after concentration. Median recovery rates were 70.1% for total protein, 71.8% for albumin, 72.0% for IgG, 76.2% for antithrombin III, and 109.4% for coagulation factor XIII. Larger ascites volumes were weakly associated with higher recovery efficiency. No serious adverse events occurred.
CART may be a safe and useful option for managing refractory ascites and protein recovery after pediatric LT while minimizing reinfusion volume.

PMID:
42663039
Bibliographic data and abstract were imported from PubMed on 28 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.